Having taken in the data from the phase IIa Action study with Tysabri (natalizumab) by Biogen Inc., investors weren't too surprised by results from the phase IIb, dose-ranging Action 2 experiment in acute ischemic stroke (AIS) that turned up no improvement compared to placebo.